Geron (GERN) Reports Data Showing Functional Dendritic Cells Can Be Created from Human Embryonic Stem Cells
More News related to GERN
- Notable Analyst Rating Changes 11/02: MOT, UFS, GNW, EL, JWN, WY, RCL, CS Upgraded; RIMM, PALM, CMCSA, ERJ, GERN Downgraded
- Needham & Co Downgrades Geron Corporation (GERN) to Hold
- Needham Downgrades Geron (GERN) to Hold
- Merriman Curhan Ford Reiterates 'Buy' Geron Corporation (GERN); Important Stem Cell Visibility
- Geron (GERN) Announces Plan to Advance Clinical Development of Stem Cell Product; Will Enable Reinitiation of Phase I Trial
Geron Corporation (Nasdaq: GERN) today announced the publication of data demonstrating that dendritic cells scalably manufactured from human embryonic stem cells exhibit the normal functions of naturally occurring human DCs found in the bloodstream. These findings support the use of hESC-derived DCs in therapeutic vaccine applications for cancer and other diseases. Substituting standardized, off-the-shelf hESC-derived DCs for current approaches using DCs obtained from individual patients may result in more cost effective and reliable approaches to cancer immunotherapy.
The study, authored by Geron scientists and collaborators Prof. Waldmann and Dr. Fairchild at the Sir William Dunn School of Pathology, University of Oxford, appears online in advance of print in the journal Regenerative Medicine. The abstract of the publication is available at http://www.futuremedicine.com/doi/abs/10.2217/rme.09.25.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
